OCGN
$2.04-0.20 (-8.93%)
Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene thera...
Recent News
Oppenheimer Initiates Ocugen (OCGN) With a Buy Rating
Ocugen, Inc. (NASDAQ:OCGN) is one of the High-Flying Penny Stocks to Buy. On March 11, Ocugen, Inc. (NASDAQ:OCGN) was initiated with an Outperform rating and a $10 price target at Oppenheimer. The firm noted that they find the company to be an upcoming leader in gene therapy for blinding ocular disorders. Oppenheimer highlighted the company’s […]
Ocugen Stock Outlook: Balancing Cash Burn and Late-Stage Data
Ocugen faces rising cash burn and dilution risk as it advances late-stage gene therapy programs, with 2026-2027 data and filings set to drive volatility.
OCGN Gene Therapy Pipeline: 2026-2027 Catalysts To Watch
Ocugen lines up key gene therapy catalysts through 2027, with pivotal data, filings, and milestones across three eye programs set to drive stock volatility.
Canaccord Initiates Coverage of Ocugen, Inc. (OCGN) with a Buy Rating and a $12 Price Target
Ocugen, Inc. (NASDAQ:OCGN) is one of the 11 Best High Volume Penny Stocks to Buy Now. On March 17, 2026, Canaccord initiated coverage of Ocugen, Inc. (NASDAQ:OCGN) with a Buy rating and a $12 price target, citing the company’s three clinical-stage programs in retinal diseases and describing early data as “interesting.” Canaccord added that the […]
Why Ocugen (OCGN) Is Up 54.0% After OCU400 Phase 3 Progress And Going Concern Spotlight
Ocugen, Inc. previously secured shareholder approval to increase authorized common shares, corrected a voting-power error in its Series C Preferred Stock designation, reported higher full-year net loss of US$67.85 million on US$4.41 million revenue for 2025, filed a US$23.24 million shelf registration, and received an auditor going concern warning, while advancing its OCU400 Phase 3 program toward planned 2026–2027 regulatory milestones. At the same time, Oppenheimer’s new research coverage...